Enrique M. Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, discusses recently approved and investigational novel agents in relapsed/refractory (R/R) multiple myeloma. Several therapeutic agents with novel mechanisms of action have been approved for use in relapsed myeloma, including selinexor, melflufen and belantamab mafodotin. Other investigational agents demonstrating promising efficacy are likely to advance in coming years. For example, CELMoD agents, novel cereblon E3 ligase modulators thought to promote the degradation of target proteins, have demonstrated efficacy in clinical trials. Agents targeting specific patient populations are also of growing interest. This interview took place during the 3rd European Society of Hematology How to Diagnose and Treat Multiple Myeloma (ESH MM) 2021 congress.